Dynamic platelet function is markedly different in patients with cancer compared to healthy donors

References

• Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160(6):809–815.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005;104(12):2822–2829. doi:10.1002/cncr.21496.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006;24(3):484–490. doi:10.1200/JCO.2005.03.8877.
   PubMed Web of Science ®Google Scholar
• Kabbani SS, Watkins MW, Ashikaga T, Terrien EF, Holoch PA, Sobel BE, Schneider DJ. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation 2001;104(2):181–186.
   PubMed Web of Science ®Google Scholar
• Buller HR, Van Doormaal FF, Van Sluis GL, Kamphuisen PW. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007;5(Suppl 1):246–254. doi:10.1111/j.1538-7836.2007.02497.x.
   PubMedGoogle Scholar
• Ambrus JL, Ambrus CM, Mink IB, Pickren JW. Causes of death in cancer patients. J Med 1975;6(1):61–64.
   PubMedGoogle Scholar
• Rickles FR, Edwards RL. Activation of blood coagulation in cancer: trousseau’s syndrome revisited. Blood 1983;62(1):14–31.
   PubMed Web of Science ®Google Scholar
• Mahmoodi BK, ten Kate MK, Waanders F, Veeger NJ, Brouwer JL, Vogt L, Navis G, van der Meer J. High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: results from a large retrospective cohort study. Circulation 2008;117(2):224–230. doi:10.1161/CIRCULATIONAHA.107.716951.
   PubMed Web of Science ®Google Scholar
• Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010;49(3):287–297. doi:10.3109/02841860903524396.
   PubMed Web of Science ®Google Scholar
• Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9(2):286–294. doi:10.1200/JCO.1991.9.2.286.
   PubMed Web of Science ®Google Scholar
• Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99(16):1232–1239. doi:10.1093/jnci/djm086.
   PubMed Web of Science ®Google Scholar
• Wall JG, Weiss RB, Norton L, Perloff M, Rice MA, Korzun AH, Wood WC. Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: a Cancer and Leukemia Group B Study. Am J Med 1989;87(5):501–504.
   PubMed Web of Science ®Google Scholar
• Cavo M, Zamagni E, Cellini C, Tosi P, Cangini D, Cini M, Valdrè L, Palareti G, Masini L, Tura S, et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 2002;100(6):2272–2273.
   PubMed Web of Science ®Google Scholar
• Kuenen BC, Levi M, Meijers JC, van Hinsbergh VW, Berkhof J, Kakkar AK, Hoekman K, Pinedo HM. Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. J Clin Oncol 2003;21(11):2192–2198. doi:10.1200/JCO.2003.08.046.
   PubMed Web of Science ®Google Scholar
• Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21(1):60–65. doi:10.1200/JCO.2003.10.066.
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Grossbard ML, Kozuch PS. The horizon of antiangiogenic therapy for colorectal cancer. Oncology (Williston Park) 2005;19(3):297–306. discussion, 8, 17-33.
   PubMed Web of Science ®Google Scholar
• Crozier JA, Swaika A, Moreno-Aspitia A. Adjuvant chemotherapy in breast cancer: to use or not to use, the anthracyclines. World J Clin Oncol 2014;5(3):529–538. doi:10.5306/wjco.v5.i3.529.
   PubMedGoogle Scholar
• Lyman GH, Khorana AA. Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol 2009;27(29):4821–4826. doi:10.1200/JCO.2009.22.3032.
   PubMed Web of Science ®Google Scholar
• Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011;11(2):123–134. doi:10.1038/nrc3004.
   PubMed Web of Science ®Google Scholar
• Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998;94(5):657–666.
   PubMed Web of Science ®Google Scholar
• Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996;84(2):289–297.
   PubMed Web of Science ®Google Scholar
• Cruz MA, Chen J, Whitelock JL, Morales LD, López JA. The platelet glycoprotein Ib-von Willebrand factor interaction activates the collagen receptor alpha2beta1 to bind collagen: activation-dependent conformational change of the alpha2-I domain. Blood 2005;105(5):1986–1991. doi:10.1182/blood-2004-04-1365.
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Handa M, Kawano K, Kamata T, Murata M, Araki Y, Anbo H, Kawai Y, Watanabe K, Itagaki I. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991;87(4):1234–1240. doi:10.1172/JCI115124.
   PubMed Web of Science ®Google Scholar
• Kulkarni S, Dopheide SM, Yap CL, Ravanat C, Freund M, Mangin P, Heel KA, Street A, Harper IS, Lanza F, et al. A revised model of platelet aggregation. J Clin Invest 2000;105(6):783–791. doi:10.1172/JCI7569.
   PubMed Web of Science ®Google Scholar
• Kent NJ, Basabe-Desmonts L, Meade G, MacCraith BD, Corcoran BG, Kenny D, Ricco AJ. Microfluidic device to study arterial shear-mediated platelet-surface interactions in whole blood: reduced sample volumes and well-characterised protein surfaces. Biomed Microdevices 2010;12(6):987–1000. doi:10.1007/s10544-010-9453-y.
   PubMed Web of Science ®Google Scholar
• Ralph A, Somers M, Cowman J, Voisin B, Hogan E, Dunne H, Dunne E, Byrne B, Kent N, Ricco AJ et al. Computational tracking of shear-mediated platelet interactions with von Willebrand factor. Cardiovasc Eng Technol. 2016.
   Google Scholar
• Cowman J, Dunne E, Oglesby I, Byrne B, Ralph A, Voisin B, Muellers S, Ricco AJ, Kenny D. Age-related changes in platelet function are more profound in women than in men. In: Scientific Reports. 2015. p. 5.
   Google Scholar
• Cowman J, Quinn N, Geoghegan S, Mullers S, Oglesby I, Byrne B, Somers M, Ralph A, Voisin B, Ricco AJ, et al. Dynamic platelet function on von Willebrand factor is different in preterm neonates and full-term neonates: changes in neonatal platelet function. J Thromb Haemost. 2016; 14(10):2027–2035.
   Google Scholar
• Cowman J, Mullers S, Dunne E, Ralph A, Ricco AJ, Malone FD, Kenny. Platelet behaviour on von Willebrand factor changes in pregnancy: consequences of haemodilution and intrinsic changes in platelet function. Sci Rep 2017;7(1):6354. doi:10.1038/s41598-017-06959-6.
   Google Scholar
• Harrison P, Lordkipanidze M. Testing platelet function. Hematol Oncol Clin North Am 2013;27(3):411–441. doi:10.1016/j.hoc.2013.03.003.
   PubMed Web of Science ®Google Scholar
• Borsig L. The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther 2008;8(8):1247–1255. doi:10.1586/14737140.8.8.1247.
   PubMed Web of Science ®Google Scholar
• Dammacco F, Vacca A, Procaccio P, Ria R, Marech I, Racanelli V. Cancer-related coagulopathy (Trousseau’s syndrome): review of the literature and experience of a single center of internal medicine. Clin Exp Med 2013;13(2):85–97. doi:10.1007/s10238-013-0230-0.
   PubMed Web of Science ®Google Scholar
• Cooke NM, Egan K, McFadden S, Grogan L, Breathnach OS, O’Leary J, Hennessy BT, Kenny D. Increased platelet reactivity in patients with late-stage metastatic cancer. Cancer Med 2013;2(4):564–570. doi:10.1002/cam4.86.
   PubMed Web of Science ®Google Scholar
• Sylman JL, Mitrugno A, Tormoen GW, Wagner TH, Mallick P, McCarty OJT. Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer. Converg Sci Phys Oncol 2017;3:2. doi:10.1088/2057-1739/aa6c05.
   Web of Science ®Google Scholar
• Lal I, Dittus K, Holmes CE. Platelets, coagulation and fibrinolysis in breast cancer progression. Breast Cancer Res 2013;15(4):207. doi:10.1186/bcr3425.
   PubMed Web of Science ®Google Scholar
• Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost 2004;30(1):95–108. doi:10.1055/s-2004-822974.
   PubMed Web of Science ®Google Scholar
• Blann AD, Gurney D, Wadley M, Bareford D, Stonelake P, Lip GY, Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coagul Fibrinolysis 2001;12(1):43–50.
   PubMed Web of Science ®Google Scholar
• Hu Q, Wang M, Cho MS, Wang C, Nick AM, Thiagarajan P, Aung FM, Han X, Sood AK, Afshar-Kharghan V. Lipid profile of platelets and platelet-derived microparticles in ovarian cancer. BBA Clin 2016;6:76–81. doi:10.1016/j.bbacli.2016.06.003.
   PubMed Web of Science ®Google Scholar
• Sabrkhany S, Kuijpers MJE, van Kuijk SMJ, Sanders L, Pineda S, Olde Damink SWM, Dingemans AC, Griffioen AW, Oude Egbrink MGA. A combination of platelet features allows detection of early-stage cancer. Eur J Cancer 2017;80:5–13. doi:10.1016/j.ejca.2017.04.010.
   PubMed Web of Science ®Google Scholar
• Wang R, Stone RL, Kaelber JT, Rochat RH, Nick AM, Vijayan KV, Afshar-Kharghan V, Schmid MF, Dong JF, Sood AK et al. Electron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian cancer. Proc Natl Acad Sci U S A 2015;112(46):14266–14271. doi:10.1073/pnas.1518628112.
   Google Scholar
• Yang X, Sun HJ, Li ZR, Zhang H, Yang WJ, Ni B, Wu YZ.Gastric cancer-associated enhancement of von Willebrand factor is regulated by vascular endothelial growth factor and related to disease severity. BMC Cancer 2015;15:80. doi:10.1186/s12885-015-1584-3.
   Google Scholar
• Mitrugno A, Tormoen GW, Kuhn P, McCarty OJ. The prothrombotic activity of cancer cells in the circulation. Blood Rev 2016;30(1):11–19. doi:10.1016/j.blre.2015.07.001.
   PubMed Web of Science ®Google Scholar
• McCarty OJ, Mousa SA, Bray PF. Konstantopoulos K. Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions. Blood 2000;96(5):1789–1797.
   PubMed Web of Science ®Google Scholar
• McCarty OJ, Jadhav S, Burdick MM, Bell WR, Konstantopoulos K. Fluid shear regulates the kinetics and molecular mechanisms of activation-dependent platelet binding to colon carcinoma cells. Biophys J 2002;83(2):836–848. doi:10.1016/S0006-3495(02)75212-0.
   PubMed Web of Science ®Google Scholar
• Egan K, Crowley D, Smyth P, O'Toole S, Spillane C, Martin C, Gallagher M, Canney A, Norris L, Conlon N, et al. Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells. PLoS One 2011;6(10):e26125. doi:10.1371/journal.pone.0026125.
   Google Scholar